PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced today that its shareholders approved all proposals put forward by the Board of Directors at the Company's fifth annual General Meeting (AGM 2026) with a large majority. The meeting, held at the Chollerhalle in Zug, saw 26,780,855 shares represented, corresponding to 80.85% of the issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term ending at the conclusion of the next annual General Meeting 2027.
Other approved proposals included the re-election of the Statutory Auditors and the Independent Proxy, as well as the approval of the maximum aggregate amount of compensation for the Board of Directors and Executive Committee. Shareholders also granted discharge to all members of the Board of Directors and Executive Committee for their activities in the financial year 2025. The Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the report on non-financial matters for the financial year 2025 were approved, along with the Remuneration Report 2025 in a separate consultative vote.
The approval of these proposals underscores shareholder confidence in PolyPeptide's strategic direction and governance. As a specialized CDMO, PolyPeptide plays a crucial role in the development and manufacturing of peptide-based therapies, particularly in metabolic diseases including GLP-1 agonists. The company's stability and strong shareholder support are vital for its continued investment in R&D and capacity expansion to meet growing global demand for peptide drugs.
The minutes of the AGM 2026 will be available within 15 days on the Company's website. The next annual General Meeting 2027 will be held on 7 April 2027. PolyPeptide Group AG, with shares listed on the SIX Swiss Exchange (ticker: PPGN), operates a global network of six GMP-certified facilities in Europe, the U.S., and India, dating back to 1952. The company's focus on peptide-based APIs positions it well in a fast-growing market, with significant exposure to metabolic diseases.
